FDA grants Celgene’s Revlimid new use as it moves toward $10B in sales

Eric Palmer

Celgene's powerhouse cancer drug generated nearly $ 5 billion for the company last year and has now gotten yet another FDA nod which analysts believe will help it double that amount within 5 years.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS